7.1 Historical Milestones: Nuremberg Code, Belmont Report & Declaration of Helsinki

Historical Milestones: Nuremberg Code, Belmont Report & Declaration of Helsinki

Exam scope note: This section cites national regulations (for example US Code of Federal Regulations provisions) because they shape day-to-day practice. ACRP states the ACRP-CP exam is referenced only to ICH Guidelines and that no country-specific framework is tested. Treat those citations as professional context; the provision examined here is the Declaration of Helsinki (2024 revision) and ICH E6(R3) Principle 1, which anchors GCP in it.

Quick Reference: Contemporary human research protection did not arise spontaneously; it was forged in response to catastrophic ethical abuses and exploitation. The Nuremberg Code (1947) established voluntary informed consent as inviolable. The Declaration of Helsinki (WMA 1964) affirmed that a subject's welfare must always supersede the interests of science or society. The Belmont Report (1979), catalyzed by the public exposure of the Tuskegee Syphilis Study, codified the foundational ethical triad: Respect for Persons, Beneficence, and Justice. Together with the 1962 Kefauver-Harris Amendments, these frameworks form the bedrock of modern Good Clinical Practice (ICH GCP).

On the ACRP-CP (ACRP Certified Professional) exam, questions concerning historical ethics assess not merely your recall of dates and names, but your understanding of why specific regulatory safeguards exist today. Understanding the historical context equips clinical research professionals to identify subtle ethical hazards, safeguard vulnerable participants, and maintain uncompromising compliance with international GCP standards.

---

1. Historical Tragedies and Catalysts for Ethical Reform

Modern clinical research regulations are essentially a codification of lessons learned from historical atrocities where human beings were treated as disposable experimental material or denied standard medical care in the pursuit of scientific data.

┌───────────────────────────────────────────────────────────────────────────┐
│               CHRONOLOGY OF ETHICAL CRISIS AND REGULATORY REACTION        │
├───────────────────────────────────────────────────────────────────────────┤
│  1932–1972: Tuskegee Syphilis Study (US PHS withholds penicillin)         │
│  1946–1947: Doctors' Trial at Nuremberg ──────► Nuremberg Code (1947)     │
│  1956–1970: Willowbrook Hepatitis Study (Infecting disabled children)   │
│  Late 1950s: Thalidomide Catastrophe ─────────► Kefauver-Harris (1962)    │
│  1964:      WMA Adopts ──────────────────────► Declaration of Helsinki    │
│  1972–1974: Tuskegee Exposed ────────────────► National Research Act (1974)│
│  1979:      Commission Publishes ────────────► Belmont Report (1979)      │
│  1996:      Harmonization ───────────────────► ICH GCP Guidelines (E6)    │
└───────────────────────────────────────────────────────────────────────────┘

A. Nazi Medical War Crimes & The Doctors' Trial (1946–1947)

During World War II, German physicians conducted horrific, non-consensual medical experiments on concentration camp prisoners in Dachau, Auschwitz, Buchenwald, and Ravensbrück. These experiments included:

• High-Altitude and Hypothermia Experiments: Subjecting prisoners to extreme atmospheric decompression and freezing water tanks to calculate survival thresholds for Luftwaffe pilots.
• Infectious Disease Inoculations: Deliberately infecting prisoners with malaria, typhus, and epidemic jaundice to test experimental therapies.
• Chemical Warfare and Trauma Experiments: Inflicting mustard gas burns, phosphorus bomb injuries, and traumatic amputations/bone grafting.
• Mass Sterilization: Evaluating surgical, radiation, and chemical methods for mass genetic annihilation.

At the conclusion of the war, the International Military Tribunal conducted the Doctors' Trial (United States v. Karl Brandt et al.) at Nuremberg. Twenty-three defendants were tried for war crimes and crimes against humanity. In August 1947, the presiding American judges issued their verdict, which included a section titled "Permissible Medical Experiments"—a 10-point standard that became globally known as the Nuremberg Code.

B. The Tuskegee Syphilis Study (1932–1972)

The Tuskegee Study of Untreated Syphilis in the Negro Male is widely recognized as the most egregious domestic research abuse in United States history:

• Sponsor & Population: Conducted by the U.S. Public Health Service (USPHS) in collaboration with the Tuskegee Institute in Macon County, Alabama. The study enrolled 600 impoverished African American sharecroppers (399 men with latent syphilis and 201 uninfected control subjects).
• The Ethical Violation: The men were never told they had syphilis. Instead, they were told they had "bad blood" (a local colloquialism encompassing anemia, fatigue, and various ailments) and were offered free medical exams, hot meals, and a $50 burial insurance benefit to secure their participation.
• Deliberate Denial of Treatment: When penicillin became recognized as the safe, validated, and curative standard of care for syphilis in the late 1940s, the researchers deliberately withheld the antibiotic from the participants. Furthermore, researchers actively prevented the men from receiving penicillin from local health clinics and military draft boards, ensuring that the men remained untreated so researchers could track the natural history of the disease through autopsy upon their deaths.
• Exposure & Regulatory Aftermath: In 1972, Peter Buxtun, a USPHS social worker and epidemiologist who had repeatedly raised ethical objections internally, leaked the details to the press (Associated Press journalist Jean Heller). The resulting public outrage led to Senate hearings chaired by Senator Edward Kennedy, the immediate termination of the study, the passage of the National Research Act of 1974, and the formation of the National Commission that authored the Belmont Report.

C. The Willowbrook Hepatitis Experiments (1956–1970s)

At the Willowbrook State School in Staten Island, New York—an overcrowded, unsanitary state institution for children with severe intellectual and developmental disabilities—Dr. Saul Krugman and associates conducted research on viral hepatitis:

• The Study Design: Newly admitted children aged 5 to 10 were deliberately inoculated with live hepatitis virus (strains isolated from feces) to study the development of immunity, differentiate Hepatitis A from Hepatitis B, and test the prophylactic efficacy of gamma globulin.
• Ethical Exploitation & Coercion: The investigators defended the study by claiming that hepatitis was already endemic at Willowbrook and that the children would contract it anyway in the cleaner research ward. However, institutional admissions were closed due to overcrowding, and desperate parents were told that the only available beds for their children were in the experimental hepatitis research unit. This created severe institutional coercion, rendering parental consent ethically invalid.

D. The Thalidomide Tragedy & The 1962 Kefauver-Harris Amendments

In the late 1950s and early 1960s, Thalidomide (Kevadon/Contergan) was aggressively marketed in Europe, Canada, and other nations as a non-barbiturate sedative and anti-emetic for morning sickness in pregnant women:

• The Teratogenic Disaster: Thalidomide caused severe phocomelia (a catastrophic congenital malformation resulting in flipper-like or absent limbs), cranial nerve palsy, and internal organ failure in over 10,000 infants worldwide.
• The FDA Defense: In the United States, FDA medical reviewer Dr. Frances Kelsey refused to approve the New Drug Application (NDA) for Richardson-Merrell, citing a lack of clinical toxicology and peripheral neuropathy safety data, despite tremendous commercial and political pressure.
• The Regulatory Transformation: The tragedy revealed that the manufacturer had already distributed millions of sample tablets to over 1,200 U.S. physicians for "investigational clinical evaluation" without patient knowledge or consent. In response, Congress unanimously passed the 1962 Kefauver-Harris Drug Amendments to the Federal Food, Drug, and Cosmetic (FD&C) Act. This landmark legislation established:
  1. Mandatory Proof of Efficacy: Drug sponsors must demonstrate substantial evidence of effectiveness through adequate and well-controlled clinical trials prior to marketing approval (not merely safety).
  2. Informed Consent Requirement: Clinical trial investigators must obtain the explicit informed consent of participants before administering investigational drugs.
  3. Adverse Reaction Reporting: Mandatory expedited reporting of adverse drug reactions to the FDA.
  4. Strict Manufacturing Standards: Formalization of Good Manufacturing Practices (GMP) and mandatory FDA factory inspections.

---

2. Comparative Matrix of Historical Abuses and Resulting Reforms

---

3. The Nuremberg Code (1947): The 10 Inviolable Principles

The Nuremberg Code represented the world's first comprehensive international standard for the ethical conduct of research involving human participants. It shifted the ethical center of gravity from the unchecked authority of the physician-investigator to the autonomous rights of the individual participant.

The 10 Directives of the Nuremberg Code:

1. Voluntary Informed Consent is Absolutely Essential: The participant must possess legal capacity to give consent, exercise free power of choice without the intervention of force, fraud, deceit, duress, or coercion, and have sufficient knowledge and comprehension of the elements of the study.
2. Fruitful Results for the Good of Society: The experiment must be designed to yield fruitful results for the good of society, unprocurable by other methods or means of study, and not random or unnecessary in nature.
3. Prior Animal Experimentation & Scientific Rationale: The experiment must be based on prior animal experimentation and a thorough knowledge of the natural history of the disease or problem under study.
4. Avoidance of Unnecessary Physical and Mental Suffering: The experiment must be conducted to avoid all unnecessary physical and mental suffering and injury.
5. Prohibition of Lethal or Disabling Experiments: No experiment should be conducted where there is an a priori reason to believe that death or disabling injury will occur, except perhaps in those experiments where the experimental physicians also serve as subjects.
6. Proportionality of Risk to Humanitarian Importance: The degree of risk to be taken must never exceed that determined by the humanitarian importance of the problem to be solved by the experiment.
7. Adequate Preparations and Protective Facilities: Proper preparations must be made and adequate facilities provided to protect the experimental subject against even remote possibilities of injury, disability, or death.
8. Execution Only by Scientifically Qualified Persons: The experiment must be conducted only by scientifically qualified persons who possess the highest degree of skill and care throughout all stages.
9. Subject's Unrestricted Liberty to Terminate Participation: The human subject must be at liberty to bring the experiment to an end at any time if they have reached a physical or mental state where continuation seems impossible.
10. Investigator's Duty to Terminate Experiment: The scientist in charge must be prepared to terminate the experiment at any stage if they have probable cause to believe that continuation is likely to result in injury, disability, or death to the subject.

Exam Note: While the Nuremberg Code established foundational ethical principles, it had practical limitations: it was formulated in the context of criminal war crimes proceedings, did not provide practical operational guidance for clinical medicine or pediatric/proxy consent, and lacked mechanisms for institutional oversight (such as IRBs).

---

4. The Declaration of Helsinki (WMA 1964 to Present)

Recognizing the limitations of the Nuremberg Code for practicing physicians conducting clinical research, the World Medical Association (WMA) adopted the Declaration of Helsinki in 1964 in Helsinki, Finland. It has been revised and amended numerous times (most notably in Tokyo 1975, Edinburgh 2000, Seoul 2008 and Fortaleza 2013). The current version was adopted at the 75th WMA General Assembly in Helsinki in October 2024 and is titled Ethical Principles for Medical Research Involving Human Participants — the 2024 revision replaced "subjects" with "participants" throughout, strengthened provisions on scientific integrity, inclusivity and data privacy, and renumbered the paragraphs. Quote the 2024 numbering: ¶7 (the purposes of research can never take precedence over the rights and interests of individual research participants), ¶22 (protocol must state funding sources and potential conflicts of interest), ¶26 (the same must be disclosed during consent), ¶34 (post-trial provisions), ¶35 (registration before recruitment of the first participant) and ¶36 (duty to publish, including negative and inconclusive results).

┌───────────────────────────────────────────────────────────────────────────┐
│               PILLARS OF THE DECLARATION OF HELSINKI (WMA)                 │
├───────────────────────────────────────────────────────────────────────────┤
│  1. PRIMACY OF THE INDIVIDUAL                                             │
│     • Well-being of the subject must take precedence over science/society │
├───────────────────────────────────────────────────────────────────────────┤
│  2. INDEPENDENT ETHICAL REVIEW                                            │
│     • Mandatory protocol review and approval by an independent committee  │
├───────────────────────────────────────────────────────────────────────────┤
│  3. STRICT INFORMED CONSENT STANDARDS                                     │
│     • Written, voluntary, informed; explicit rules for proxy/LAR consent  │
├───────────────────────────────────────────────────────────────────────────┤
│  4. PLACEBO & STANDARD-OF-CARE RESTRICTIONS                               │
│     • New interventions tested against BEST PROVEN intervention           │
│     • Placebo permitted only when no proven therapy exists OR for         │
│       compelling scientific reasons with NO risk of serious harm          │
├───────────────────────────────────────────────────────────────────────────┤
│  5. POST-TRIAL ACCESS & BENEFIT SHARING                                   │
│     • Sponsors must provide post-trial access to proven beneficial drugs  │
├───────────────────────────────────────────────────────────────────────────┤
│  6. PUBLICATION & TRANSPARENCY INTEGRITY                                  │
│     • Negative, inconclusive, and positive results must be published      │
└───────────────────────────────────────────────────────────────────────────┘

Core Tenets of the Declaration of Helsinki:

• Primacy of the Human Subject: Paragraph 7 of the 2024 revision declares that these purposes "can never take precedence over the rights and interests of individual research participants."
• The Physician's Ethical Duty: Binds the physician to the Geneva declaration: "The health of my patient will be my first consideration."
• Independent Ethics Committee (IEC) Mandate: Research protocols must be submitted for consideration, comment, guidance, and approval to the concerned research ethics committee before the study begins.
• Scientific Validity & Environmental Responsibility: Research must conform to generally accepted scientific principles, be based on thorough knowledge of scientific literature, and respect environmental welfare.
• The Placebo Controversy (Paragraph 33): The Declaration takes a restrictive stance on placebo controls. The benefits, risks, burdens, and effectiveness of a new intervention must be tested against those of the best proven intervention(s). A placebo or no treatment is acceptable only when:
  1. No proven intervention exists; or
  2. For compelling and scientifically sound methodological reasons, the use of any intervention less effective than the best proven one, the use of placebo, or no intervention is necessary to determine the efficacy or safety of an intervention, and the patients will not be subject to additional risks of serious or irreversible harm.
• Post-Trial Provisions (Paragraph 34): In advance of a clinical trial, sponsors, researchers, and host country governments must make provisions for post-trial access for all participants who still need an intervention identified as beneficial in the trial.
• Publication Ethics & Trial Registration (Paragraphs 35–36): Every clinical trial must be registered in a publicly accessible database (e.g., ClinicalTrials.gov) before recruitment. Researchers have an ethical obligation to publish both positive and negative/inconclusive results, disclose conflicts of interest, and avoid duplicate or distorted publications.

---

5. The Belmont Report (1979) and National Research Act of 1974

Following the public exposure of the Tuskegee Syphilis Study, the United States Congress enacted the National Research Act of 1974, creating the National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research.

The Commission convened at the Smithsonian Institution's Belmont Conference Center in 1976 and issued its landmark summary in September 1979: The Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research.

The Foundational Triad of the Belmont Report:

1. Respect for Persons: Acknowledges personal autonomy and mandates the protection of individuals with diminished autonomy. Operationalized through the Informed Consent process (information, comprehension, voluntariness).
2. Beneficence: Obligates researchers to "do no harm" (non-maleficence) and to maximize possible benefits while minimizing possible harms. Operationalized through the systematic Assessment of Risks and Benefits.
3. Justice: Mandates fairness in the distribution of research burdens and benefits, requiring that vulnerable populations not be exploited for the benefit of more privileged classes. Operationalized through the equitable Selection of Subjects.

Codification into Federal Regulations (The Common Rule & FDA CFRs)

The principles of the Belmont Report served as the direct philosophical blueprint for U.S. federal regulations:

• 45 CFR 46 (Department of Health and Human Services - Common Rule): Governs federally funded research, establishing subparts for vulnerable populations (Subpart B: Pregnant Women/Fetuses; Subpart C: Prisoners; Subpart D: Children).
• 21 CFR 50 (FDA Informed Consent): Establishes mandatory elements and documentation of informed consent for FDA-regulated products.
• 21 CFR 56 (FDA Institutional Review Boards): Establishes the composition, operation, review criteria, and records of IRBs.

---

6. Comparative Architecture of Global Ethical Frameworks